Elevated levels of BRAF(V600) mutant circulating tumor DNA and circulating hepatocyte growth factor are associated with poor prognosis in patients with metastatic melanoma Journal Article


Authors: Lu, W.; Burton, L.; Larkin, J.; Chapman, P. B.; Ascierto, P. A.; Ribas, A.; Robert, C.; Sosman, J. A.; McArthur, G. A.; Chang, I.; Caro, I.; Penuel, E.; Yan, Y. B.; Wongchenko, M. J.
Article Title: Elevated levels of BRAF(V600) mutant circulating tumor DNA and circulating hepatocyte growth factor are associated with poor prognosis in patients with metastatic melanoma
Abstract: Purpose We performed a retrospective exploratory analysis to evaluate the prognostic and predictive effect of two circulating biomarkers, BRAF(V600) mutant circulating tumor DNA (ctDNA) and circulating hepatocyte growth factor (cHGF), in metastatic melanoma. Materials and Methods This study evaluated patients from BRIM-3, a phase III trial comparing vemurafenib and dacarbazine in 675 patients with BRAF(V600) mutated advanced melanoma. ctDNA was measured using droplet digital polymerase chain reaction, and cHGF was measured by enzyme-linked immunosorbent assay. Overall survival (OS) was estimated using the Kaplan-Meier method, and hazard ratios (HRs) were estimated using Cox proportional hazards modeling. Partitioning analysis was used to group patients into risk categories. Results Patients with elevated levels of baseline BRAF(V600) ctDNA had significantly shorter median OS than those with undetectable levels of ctDNA (vemurafenib arm, 9.9 v 21.4 months, respectively, and dacarbazine arm: 6.1 v 21.0 months, respectively). Median OS was also shorter in patients with high levels of cHGF compared with those with low cHGF (vemurafenib arm, 11.9 v 17.3 months, respectively, and dacarbazine arm, 6.1 v 14.4 months, respectively). In a multivariable proportional hazards model with adjustment for lactate dehydrogenase, Eastern Cooperative Oncology Group status, disease stage, and treatment, ctDNA and cHGF were both independent prognostic factors for OS, (HR, 1.75; 95% CI, 1.35 to 2.28 for high v undetectable ctDNA; HR, 1.24; 95% CI, 1.00 to 1.53 for high v low cHGF). Using partitioning analysis, we found that patients with elevated ctDNA combined with elevated cHGF constituted the highest risk group with significantly shorter OS. Conclusion Here, we report that BRIM-3 patients with high levels of ctDNA and cHGF have worse OS regardless of treatment and that these factors are independent prognostic markers for metastatic melanoma. (C) 2018 by American Society of Clinical Oncology
Keywords: mutation; analysis; serum; plasma; braf; resistance; follow-up; heterogeneity; clinical-significance; cell-free dna; droplet digital pcr
Journal Title: JCO Precision Oncology
Volume: 2
ISSN: 2473-4284
Publisher: American Society of Clinical Oncology  
Date Published: 2018-01-01
Language: English
ACCESSION: WOS:000462079600001
DOI: 10.1200/po.17.00168
PROVIDER: wos
Notes: Source: Wos
Altmetric Score
MSK Authors
  1. Paul Chapman
    259 Chapman